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ABSTRACT 
Background. Therapy with aspirin and one of the platelet P2Y12 receptor inhibitors, preferably ticagrelor or 
prasugrel, is the mainstay of acute myocardial infarction (AMI) treatment. Morphine is the most commonly 
used analgesic in AMI patients. The IMPRESSION study was the first randomized trial to confirm that 
morphine use in this clinical setting leads to a delayed and attenuated exposure to ticagrelor and its active 
metabolite (AR-C124910XX). The mechanism underlying this drug-drug interaction remains hypothetical.
Material and methods. A post hoc sub-analysis of the IMPRESSION study, a phase IV, single center, ran-
domized, double-blind, placebo-controlled trial, was performed to examine whether morphine administration 
interferes with the proportion of AR-C124910XX produced from ticagrelor in AMI patients. Pharmacokinetic 
results of all subjects pretreated with placebo (n = 35) and morphine (n = 35) were analyzed. The ratio of 
total exposure to AR-C124910XX to total exposure to ticagrelor for 12 h was used to illustrate the rate of 
ticagrelor metabolism. Total exposure to investigated compounds was measured as the area under the 
plasma concentration-time curve (AUC). 
Results. The ratios of AUC(0–12) for AR-C124910XX to AUC(0–12) for ticagrelor were comparable between 
morphine and placebo pretreated patients (20.9 [13.9–34.6] v. 24.7 [18.1–29.6] %; p = 0.58). Importantly, 
visual inspection of the relationship between AUC(0–12) for AR-C124910XX and AUC(0–12) for ticagrelor re-
vealed that regression lines for the morphine and placebo groups were located closely to each other, with 
a tendency for superimposing. Additionally, we observed similar values of slope coefficients for both study 
arms in the linear regression equations illustrating the relationship between AUC(0–12) for AR-C124910XX 
and AUC(0–12) for ticagrelor (0.19 [± 0.03] v. 0.21 [± 0.04]; p for the statistical significance of both slope 
coefficients < 0.0001).
Conclusions. In the IMPRESSION study, conversion of ticagrelor to AR-C124910XX in AMI patients was 
not affected by morphine administration.
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Introduction
Excessive platelet reactivity is considered one of 
the key factors predisposing to the occurrence of acute 
myocardial infarction (AMI) and stent thrombosis. Dual 
antiplatelet therapy with aspirin and one of the platelet 
P2Y12 receptor inhibitors remains the cornerstone 
of AMI treatment [1, 2]. The current guidelines of the 
European Society of Cardiology recommend the use 
of ticagrelor or prasugrel in AMI patients [3, 4]. Tica-
grelor and prasugrel are preferred over clopidogrel in 
this setting, and, according to the guidelines, the use 
of the latter should be restricted to the situations when 
ticagrelor or prasugrel are not available or are contra-
indicated [3, 4]. In contrast to prasugrel, therapy with 
ticagrelor is also advocated in AMI patients managed 
without coronary revascularization [3, 4]. Despite 
multiple pharmacokinetic and pharmacodynamic dif-
ferences among the antiplatelet agents, the common 
feature of clopidogrel, prasugrel and ticagrelor is their 
oral route of administration. Cangrelor, the first recently 
approved intravenous P2Y12 receptor inhibitor, is still 
not commercially available in many European countries, 
including Poland.
The superiority of ticagrelor over clopidogrel in 
patients with acute coronary syndromes has been 
demonstrated in the Platelet Inhibition and Patient 
Outcomes (PLATO) trial. In this randomized study, 
therapy with ticagrelor, when compared with clopidogrel 
treatment, decreased the rate of major cardiovascular 
events (a composite of death from vascular causes, 
myocardial infarction, stroke) and all-cause mortality, 
without a concomitant increase in the occurrence of 
overall major bleeding complications [5].
Ticagrelor is an oral, reversible, noncompetitive 
P2Y12 receptor inhibitor, which is characterized by 
a potent and uniform antiplatelet action [6]. Contrary to 
clopidogrel and prasugrel, ticagrelor is an active drug 
which does not require metabolism to inhibit platelet 
P2Y12 receptor. Therefore, it exerts its antiplatelet effect 
immediately after absorption. In addition, ticagrelor is 
extensively metabolized to about ten compounds. Tica-
grelor main active metabolite, AR-C124910XX, which is 
formed by ticagrelor O-de-ethylation through cytochrome 
P450 CYP3A4 and CYP3A43A5 enzymes, has a similar 
P2Y12 receptor potency as the parent drug and seems 
to exert antiplatelet action comparable to ticagrelor [7, 8]. 
The concentration of AR-C124910XX is reported to be 
approximately one third of the parent drug [7–9]. A pre-
dictable and linear pharmacokinetics of ticagrelor and AR-
C124910XX have been demonstrated in a wide spectrum 
of patients, including those with stable coronary artery 
disease and acute coronary syndromes [10, 11]. Both, 
circulating ticagrelor and its active metabolite, undergo 
N-dealkylation and/or glucuronidation, and are finally 
eliminated via feces and urine in an inactive state [8].
Pain relief is crucial in the treatment of AMI patients 
not only for the humane reasons. Effective chest pain 
alleviation reduces heart rate and blood pressure; there-
fore, it improves the balance between cardiomiocytes’ 
oxygen demand and supply [12]. Although a few new 
analgesics have been developed in the recent years, 
morphine remains the most commonly used painkiller 
in patients with AMI and is continuously endorsed in 
the subsequent guidelines for the treatment of acute 
coronary syndromes [3, 4]. Moreover, the extensive 
experience in the use of morphine in cardiac intensive 
care units and emergency departments only assures its 
position in the everyday practice in this setting. Never-
theless, adverse effects of morphine occur frequently. 
Respiratory depression, hypotension and impaired 
propulsive motility of gastrointestinal tract, which may 
lead to emesis, are only a few examples of the potential 
side effects of morphine use [12, 13]. In particular, the 
influence exerted by morphine on the gastrointestinal 
tract constitutes the danger of a negative impact on 
absorption of the orally administered drugs, which 
may lead to an attenuated and delayed action of those 
compounds. The above mentioned problem largely 
concerns patients presenting with AMI who require fast 
and strong platelet blockade, but often simultaneously 
need effective analgesic treatment.
The results of our recently published Influence 
of Morphine on Pharmacokinetics and Pharmacody-
namics of Ticagrelor in Patients with Acute Myocardial 
Infarction (IMPRESSION) study confirmed the alleged 
drug-drug interaction between ticagrelor and mor-
phine [14]. This study was the first randomized trial 
to document a delayed and attenuated exposure to 
ticagrelor and AR-C124910XX in AMI patients caused 
by intravenous administration of morphine prior to the 
loading dose of ticagrelor [15]. However, the detailed 
mechanism underlying this drug-drug interaction re-
mains hypothetical. Therefore, we conducted this post 
hoc sub-analysis of the pharmacokinetic results of the 
IMPRESSION study in order to test the hypothesis that 
morphine administration may affect the rate of ticagrelor 
to AR-C124910XX metabolism in AMI patients.
Materials and methods
Study and sub-analysis design
The IMPRESSION study was a phase IV, single center, 
randomized, double-blind, placebo-controlled trial which 
was aimed to examine the impact of morphine on plas-
ma concentrations of ticagrelor and AR-C124910XX, as 
well as to evaluate morphine’s influence on the antiplate-
let effect of ticagrelor and its active metabolite [14, 15]. 
The diagnosis of AMI was made according to the 
third universal definition of myocardial infarction [16]. 
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Briefly, the IMPRESSION study included  P2Y12 receptor 
inhibitor-naive patients, aged 18 to 80, who have not 
received morphine during the current AMI. Pain free 
subjects, patients who required analgesia on admission 
due to high pain intensity, patients with signs and symp-
toms of acute heart failure or known contraindications to 
ticagrelor were not considered for enrollment [14, 15]. 
The primary endpoint of the IMPRESSION study was 
the area under the plasma concentration-time curve 
(AUC(0–12)) for ticagrelor during the first 12 h after ad-
ministration of the ticagrelor loading dose. Secondary 
endpoints of the trial, among others, included AUC(0–12) 
for AR-C124910XX [14, 15]. The detailed study design, 
complete inclusion and exclusion criteria, entire list of 
the study endpoints, sample size calculation and the re-
sults were previously described and published [14, 15]. 
We recruited 74 patients for the IMPRESSION trial. 
However, a total of 70 patients were included in the 
primary analysis (one patient had STEMI diagnosis 
not confirmed and three patients, due to chest pain 
aggravation, required morphine administration outside 
the study protocol, which resulted in their exclusion 
from the further participation in the trial) [14, 15]. 
Both ST-segment elevation myocardial infarction 
(STEMI) and non-ST-segment elevation myocardial 
infarction (NSTEMI) patients admitted to the study site 
(Cardiology Clinic, Dr. A. Jurasz University Hospital, 
Bydgoszcz, Poland) were randomly assigned to one of 
the study arms. Subjects allocated to the intervention 
arm received intravenous morphine before they were 
loaded with 180 mg of ticagrelor. Patients in the control 
arm were injected with placebo (0.9% saline) before 
they were given a 180 mg ticagrelor loading dose [15]. 
A total of 70 AMI patients (35 morphine pre-treated 
patients and 35 placebo pre-treated patients) com-
pleted the pharmacokinetic and pharmacodynamic 
assessment [14]. In the IMPRESSION study, the ad-
ministration of morphine, as compared with placebo, 
was associated with the lower total exposure to both 
ticagrelor and its active metabolite AR-C124910XX 
within the first 12 h after the administration of a 180 mg 
ticagrelor loading dose, as measured by AUC(0–12). 
Morphine decreased the exposure to ticagrelor within 
the first 12 h of the treatment by 36% (p = 0.003) and 
to AR-C124910XX by 37% (p = 0.008). Moreover, the 
patients in the morphine arm required more time to 
reach maximal plasma concentration of ticagrelor 
compared with the subjects from the placebo arm 
(4 [3–12] v. 2 [2–4] h; p = 0.004) and had a reduced 
maximal concentration of ticagrelor (1156 ± 771 v. 
1683 ± 847 ng/mL; p = 0.006) [14]. Consequently, 
pharmacodynamic assessment with three different 
methods showed an attenuated antiplatelet effect of 
ticagrelor and a greater prevalence of high platelet 
reactivity in the morphine group [14].
In this sub-analysis, we selected the ratio of total 
exposure to AR-C124910XX to total exposure to ticagre-
lor over time as a potential marker which may indicate 
the difference in conversion of ticagrelor to its active 
metabolite between the morphine and placebo arms.
The IMPRESSION study was approved by the Ethics 
Committee of the Nicolaus Copernicus University in 
Toruń, Collegium Medicum in Bydgoszcz (study ap-
proval reference number KB 111/2014) and was con-
ducted in accordance with Good Clinical Practice guide-
lines, and the principles contained in the Declaration of 
Helsinki. It was also registered within ClinicalTrials.gov, 
a registry and results database of publicly and privately 
supported clinical studies (ClinicalTrials.gov Identifier: 
NCT02217878). All enrolled patients provided written 
informed consent to participate in the study.
Endpoints
The primary endpoint of this sub-analysis was the 
ratio of AUC(0–12) for AR-C124910XX to AUC(0–12) for 
ticagrelor expressed as a percentage.
Blood sampling
Blood samples were drawn at eight pre-defined 
time points according to the blood sampling schedule 
(pre-loading dose of ticagrelor and 30 min, 1 h, 2 h, 3 h, 
4 h, 6 h, 12 h post loading dose) [15]. Blood samples 
for a pharmacokinetic evaluation were collected through 
a venous cannula (18G) inserted into a forearm vein 
and the first 3–5 mL of blood were discarded, mainly 
to avoid spontaneous platelet activation which could 
affect the pharmacodynamic outcomes. Immediately 
after collection, blood samples were centrifuged at 
1500 revolutions per minute for 15 minutes. Subse-
quently, plasma samples were stored at –80°C until the 
pharmacokinetic analysis. 
Pharmacokinetic assessment
Plasma concentrations of ticagrelor and AR-C124910XX 
were determined using liquid chromatography coupled 
with tandem mass spectrometry in the Department of 
Medicinal Chemistry, Collegium Medicum in Bydgo-
szcz, Nicolaus Copernicus University in Toruń, Poland. 
Lower limits of quantification were 4.69 ng/mL for both 
ticagrelor and AR-C124910XX [14].
Statistical analysis
Statistical calculations were performed using the 
Statistica 12.5 package (StatSoft, Tulsa, OK, USA) 
and MedCalc 12.0 (MedCalc Software, Mariakerke, 
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Belgium) statistical software. Pharmacokinetic calcula-
tions were performed using the Matlab R2014 software 
(Mathworks, Natick, MA, USA). The Shapiro-Wilk test 
was used to demonstrate whether the investigated 
continuous variables were normally distributed. There-
fore, continuous variables with and without normal 
distribution were presented as mean values ± standard 
deviations or as medians and their interquartile ranges, 
respectively. The trapezoidal rule was applied to cal-
culate AUC. Depending on the presence or absence 
of the normal distribution, continuous variables were 
compared between the study arms with the Student’s 
t-test for independent samples or the Mann-Whitney 
U-test. Independent categorical variables were com-
pared using the c2 test with the Yates’ correction if 
required. Linear regression analysis and the Spearman 
rank correlation coefficients were applied to evaluate the 
association between AUC(0–12) for AR-C124910XX and 
AUC(0–12) for ticagrelor. Two sided p-values < 0.05 were 
considered significant.
Results
Baseline characteristics of the IMPRESSION study 
population were well balanced between both study 
arms (Tab. 1).
The administration of morphine as compared with 
placebo led to a lower total exposure to both ticagrelor 
(AUC(0–12): 6307 ± 4359 v. 9791 ± 5136 ng × h/mL; 
p = 0.003) and its active metabolite AR-C124910XX 
(AUC(0–12): 1503 ± 1138 v. 2388 ± 1555 ng × h/mL; 
p = 0.008) within the first 12 h after the administration 
of the 180 mg ticagrelor loading dose [14].
Importantly, the conversion of ticagrelor to its active 
metabolite within the first 12 h after the loading dose 
of ticagrelor, as measured by the ratio of AUC(0–12) for 
AR-C124910XX to AUC(0–12) for ticagrelor, was compara-
ble in patients assigned to the morphine and placebo arms 
(20.9 [13.9–34.6] v. 24.7 [18.1–29.6] %; p = 0.58) (Fig. 1). 
It is worthy of note that three patients in the morphine 
arm had AUC(0–12) for AR-C124910XX of 0 ng × h/mL, 
and subsequently the ratio of AR-C124910XX exposure 
to ticagrelor exposure was 0%. In all those cases ticagre-
lor was not detected in any of the blood samples until 
the measurement point at 12 h after the loading dose 
of ticagrelor, and even then it was present in minimal 
concentrations only, which seems to be a reasonable 
explanation for the lack of AR-C124910XX in blood 
samples obtained within the first 12 h in those subjects.
Notably, visual inspection of the relationship be-
tween AUC(0–12) for AR-C124910XX and AUC(0–12) for ti-
cagrelor revealed that regression lines for the morphine 
and placebo groups were located closely to each other, 
Table 1. Baseline characteristics of the study patients
Variable
Morphine Placebo
p-value(n = 35) (n = 35)
Age (years) 60.7 ± 10.5 62.5 ± 10.5 0.47
Female 12 (34%) 7 (20%) 0.19
Body mass index [kg/m2] 27.6 ± 4.3 27.4 ± 4.0 0.87
STEMI 24 (69%) 21 (60%) 0.45
NSTEMI 11 (31%) 14 (40%) 0.45
Metoclopramide use 1 (3%) 0 (0%) n/a
Hypertension 15 (43%) 21 (60%) 0.15
Diabetes mellitus 8 (23%) 5 (14%) 0.36
Dyslipidemia 30 (86%) 31 (89%) n/a
Current smoker 17 (55%) 14 (45%) 0.47
Prior AMI 5 (14%) 8 (23%) 0.20
Prior PCI 4 (11%) 9 (26%) 0.12
Prior CABG 0 (0%) 0 (0%) n/a
Peripheral arterial disease 3 (9%) 1 (3%) 0.31
Chronic renal disease 1 (3%) 2 (6%) 0.31
AMI — acute myocardial infarction; CABG — coronary artery bypass grafting; n/a — not applicable; NSTEMI — non-ST-segment elevation  
myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction
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Figure 1. Comparison of the ratios of AR-C124910XX 
exposure to ticagrelor exposure during the first 12 h after 
the administration of a 180 mg ticagrelor loading dose in 
the morphine and placebo groups. Boxes and whiskers 
represent medians, interquartile ranges and extreme 
values
with a tendency for superimposing (Fig. 2). Addition-
ally, we observed similar values of slope coefficients 
for both study arms in the linear regression equations 
illustrating the relationship between AUC(0–12) for 
AR-C124910XX and AUC(0–12) for ticagrelor (morphine- 
-treated patients: AUC(0–12) for AR-C124910XX = 0.19 
(± 0.03) × AUC(0–12) for ticagrelor + 317.99 (± 240.65); 
p for the slope coefficient < 0.0001; morphine-na-
ive patients: AUC(0–12) for AR-C124910XX = 0.21 
(± 0.04) × AUC(0–12) for ticagrelor + 363.70 (± 424.57); 
p for the slope coefficient < 0.0001). Strong positive 
correlations between the AUC(0–12) for AR-C124910XX 
and AUC(0–12) for ticagrelor were present in both mor-
phine- and placebo-pretreated patients (morphine arm: 
RS = 0.75; p for the statistical significance of the RS 
correlation coefficient < 0.05; placebo arm: RS = 0.79; 
p for the statistical significance of the RS correlation 
coefficient < 0.05), without any statistically significant 
difference between the values of the Spearman rank 
correlation coefficients (p = 0.69).
Discussion
The results of this post hoc analysis indicate that 
within the first 12 h after the administration of the ticagre-
lor loading dose, the rate of ticagrelor to AR-C124910XX 
metabolism is similar in patients presenting with AMI 
regardless of the morphine administration. 
Ticagrelor is predominantly metabolized by cyto-
chrome P450 CYP3A4, however, CYP3A5 enzyme also 
participates in this process to a lesser extent. The list of 
compounds known to affect metabolism of ticagrelor 
includes both CYP3A4 inducers and inhibitors. CYP3A4 
inducers (e.g. rifampicin) lead to a lower exposure to 
this P2Y12 receptor inhibitor by enhancing ticagrelor 
metabolism [17], which may cause insufficient platelet 
inhibition and expose patients at increased risk of throm-
botic complications [18]. Strong CYP3A4 inhibitors 
(e.g. ketoconazole) act conversely [19]. Most opioids 
are metabolized through CYP-mediated oxidation, 
including CYP3A4, and have significant potential for 
drug-drug interactions [20]. However, morphine follows 
a different metabolic pathway and is considered to have 
relatively smaller burden of CYP-mediated drug inter-
actions [20], which seems to be in line with the results 
of our sub-analysis.
According to the study by Teng et al., AR-C124910XX, 
the main active metabolite of ticagrelor, can be found 
in plasma in the concentration of approximately one-
third of the concentration of ticagrelor [8]. In general, 
the results of our sub-analysis correspond with the 
previously described pharmacokinetic features of 
ticagrelor [8]. Importantly, in this study we provide 
the new insights regarding the ticagrelor-morphine 
interaction. Briefly, we found that the ratios of AUC(0–12) 
for AR-C124910XX to AUC(0–12) for ticagrelor were 
comparable in both morphine and placebo pretreated 
patients. These results are additionally strengthened 
by the findings coming from the visual inspection of 
the relationship between AUC(0–12) for AR-C124910XX 
and AUC(0–12) for ticagrelor, which revealed closely 
located regression lines for the morphine and placebo 
groups, with a tendency for superimposing. Moreover, 
we observed similar values of slope coefficients for both 
study arms in the linear regression equations illustrating 
the relationship between AUC(0–12) for AR-C124910XX 
and AUC(0–12) for ticagrelor.
Figure 2. Relationship between AUC(0–12) for AR-C124910XX 
and AUC(0–12) for ticagrelor during the first 12 h after the 
administration of a 180 mg ticagrelor loading dose in the 
morphine and placebo groups
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In the light of the current sub-analysis, an attenuation 
and delay in the exposure to AR-C124910XX observed 
in the morphine arm of the IMPRESSION study [14] are 
most likely caused by decreased concentrations of the 
parent compound, probably resulting from morphine-in-
duced impaired gastric emptying, lower intestinal motili-
ty and higher incidence of vomiting. The activation of the 
opioid receptors located in the myenteric plexus and in 
the intestines was previously demonstrated to decrease 
propulsive motility and secretion of the gastro-intestinal 
tract [13]. The results obtained in this study expand 
the knowledge regarding the pharmacokinetics of tica-
grelor, but also underline the need of elucidation and 
a detailed examination of the mechanisms underlying 
the attenuated and delayed exposure to ticagrelor and 
its active metabolite in AMI patients. 
Study limitations
Several limitations of our study need to be acknowl-
edged. Firstly, the IMPRESSION study was not designed 
to investigate the detailed mechanisms responsible for 
decreased plasma concentrations of ticagrelor and its 
active metabolite in morphine-treated patients. There-
fore, the function of cytochrome P450 CYP3A4 and 
CYP3A5 enzymes, which are involved in ticagrelor’s 
transformation into AR-C124910XX, were not directly 
examined and our observations are only hypothesis 
generating. Additionally, this sub-analysis may be un-
derpowered to detect a minor impact of the morphine 
administration on the conversion of ticagrelor to its ac-
tive metabolite. Moreover, morphine dosing regimens, 
different from those employed in the IMPRESSION 
study, might have a greater influence on ticagrelor’s 
metabolism. Finally, the present sub-analysis was per-
formed post hoc and was not predefined.
Conclusions
In this sub-analysis of the IMPRESSION study, we 
did not find any evidence that the extent of ticagre-
lor conversion to AR-C124910XX is affected by the 
morphine administration. A decreased exposure to 
AR-C124910XX in the morphine arm compared with the 
placebo arm of the IMPRESSION study was most likely 
caused by a proportional attenuation of the exposure 
to the parent drug. 
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